Skip to main content
Premium Trial:

Request an Annual Quote

Ipsogen Board OKs Acquisition by Qiagen

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The board of directors of French companion diagnostics firm Ipsogen has approved the terms of a proposed acquisition by Qiagen.

Qiagen announced its plans to buy the firm in a deal valued at around €70 million ($101 million) a few weeks ago. At the time, Qiagen entered into exclusive negotiations with a group of Ipsogen shareholders to purchase about 47 percent of the company's outstanding shares currently held or controlled by company co-founders and board members. After the purchase agreement has been signed and the purchase is completed, Qiagen will begin to acquire all remaining shares of Ipsogen.

Qiagen is paying €12.90 per share to acquire a 47 percent stake in the company and to purchase all remaining shares afterward.

After the close of the market Friday, Qiagen said that Ipsogen's board had voted in favor of the deal and gave a favorable preliminary opinion on the subsequent public tender offer. Qiagen also entered into agreements with shareholders holding 61 percent of the share capital of Ipsogen to sell their shares to Qiagen.

As of June 12, Qiagen expects Ipsogen will become a fully consolidated subsidiary of the firm.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.